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Anesthetic agents might possess arrhythmogenic or
antiarrhythmic properties due to their effects on car-
diac electrical activity [1]. These effects of anesthetic
agents can be determined on 12-lead electrocardio-
grams (ECGs) by measuring P-wave dispersion (Pwd)
and QT and corrected QT (QTc) intervals [1–5]. Pwd is
defined as the difference between the maximum and
minimum P-wave duration in any of 12 leads of sur-
face ECGs. Pwd is a simple non-invasive ECG indi-
cator of atrial arrhythmia such as atrial flutter or
fibrillation [1–5]. Increased Pwd is accepted as an
independent predictor of postoperative atrial fibrilla-
tion after coronary artery bypass graft surgery [6,7].
QT and QTc intervals are electrocardiographic indi-
cators of ventricular repolarization. Prolongation of
the QTc interval is associated with an increased risk
of sudden death because of fatal ventricular arrhyth-
mia such as torsade de pointes [2,4,5]. Previous stud-
ies have shown that Pwd and QTc intervals might be
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The present study compared the effects of anesthesia induction with sevoflurane and propofol on
hemodynamics, P-wave dispersion (Pwd), QT interval and corrected QT (QTc) interval. A total of
72 adult patients were included in this prospective study. All patients had control electrocardio-
grams (ECGs) before anesthesia induction. Anesthesia was induced with sevoflurane inhalation
or intravenous propofol. Electrocardiography for all patients was performed during the 1st and
3rd minutes of induction, 3 minutes after administration of muscle relaxant, and at 5 minutes and
10 minutes after intubation. Pwd and QT intervals were measured on all ECGs. QTc intervals
were determined using the Bazett formula. There was no significant difference in Pwd and QT
and QTc intervals on control ECGs. In the sevoflurane group, except for control ECGs, Pwd and
QTc interval on all ECGs were significantly longer than those in the propofol group (p < 0.05). We
conclude that propofol should be used for anesthesia induction in patients with a predisposition
to preoperative arrhythmias, and in those whose Pwd and QTc durations are prolonged on 
preoperative ECGs.
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extended in conditions such as diabetes mellitus [8,9]
prehypertension [10,11], subarachnoid hemorrhage
[5], malnutrition [4] and obesity [12,13].
In patients with prolonged Pwd and QTc interval,
the choice of anesthetic is important. The effects of
anesthesia induction with sevoflurane and propofol
on QT and QTc intervals have been studied; however,
little research has been done on their effects on Pwd.
In this study, we hypothesized that sevoflurane and
propofol would affect Pwd. To test our hypothesis,
we investigated ECGs of patients during anesthesia
induction with sevoflurane and propofol, and ana-
lyzed Pwd and QT and QTc durations.
METHODS
Patients
After obtaining the approval from the hospital ethics
committee, we enrolled 72 adult patients aged 18–50
years, with American Society of Anesthesiologists
(ASA) physical status I and II, who were scheduled
for elective non-cardiac surgery. Written informed
consent was obtained from all participants. The fol-
lowing were recorded: demographic data; age; ASA
category; serum sodium, potassium, calcium, chlo-
rine and magnesium levels; and body mass index
(BMI).
Thirty minutes prior to anesthesia induction, 
all patients were premedicated with intramuscular
0.07 mg/kg midazolam (Dormicum; Roche, Basel,
Switzerland). In the operating theater, a 20-gauge can-
nula was used for intravenous access and 5–7 mL/kg
Ringer’s Lactate (Ringer Laktat; Polifarma, Istanbul,
Turkey) infusion was started. Baseline arterial blood
pressure, peripheral oxygen saturation, and ECG
records were obtained.
All patients were subjected to standard 12-lead
echocardiography using a Hewlett Packard PageWriter
300pi ECG device (Andover, MA, USA), and control
ECGs were recorded at a paper speed of 50 mm/sec
with an amplitude of 1 mV/cm prior to anesthesia
induction. After ECGs were recorded, patients were
randomly divided into two groups using a random
samples table.
Exclusion criteria
Exclusion criteria included: pregnancy, anorexia
(BMI < 18 kg/m2) [4], obesity (BMI > 30 kg/m2) [3],
chronic liver and kidney diseases, electrolyte disor-
ders, diabetes mellitus, hypothyroidism or hyperthy-
roidism, alcohol addiction, coronary artery disease,
Chagas disease, cardiomyopathy, arterial hyperten-
sion, atrial and/or ventricular hypertrophy on ECG,
arrhythmia, cardiomegaly, valvular disease, cardiac
insufficiency, and use of medication that led to ex-
tended QT intervals [1–5].
Anesthesia induction
In the sevoflurane group (n = 36), anesthesia was in-
duced using the tidal volume inhalational induction
technique by breathing 7% sevoflurane (Sevorane;
Abbott Laboratories, Maidenhead, Berks, UK) in 6 L/
min fresh gas flow for 2 minutes. Anesthesia was main-
tained using 3% sevoflurane. In the propofol group
(n=36), anesthesia was induced by intravenous 2.5mg/
kg propofol (Propofol 1% Fresenius; Fresenius Kabi,
Uppsala, Sweden). Anesthesia was maintained with
infusion of 6 mg/kg/hr propofol.
Both groups received 0.1mg/kg vecuronium (Blok-
L; Mustafa Nevzat Ilac San., Istanbul, Turkey) for
muscle relaxation at the 3rd minute of induction. Intu-
bation was performed at 3 minutes after veruconium
administration. Throughout the entire study, a 60/
40% oxygen/air mixture was used as a carrier gas.
Patients were ventilated with end-tidal CO2 at
35–40 mmHg.
We planned to give intravenous 0.5 mg atropine
(Atropin, Biofarma, Istanbul, Turkey) to patients with
heart rate <50 beats/min, and 5mg ephedrine (Efedrin,
Osel, Istanbul, Turkey) to those with mean arterial
blood pressure < 30% of the control level for a mini-
mum of 1 minute.
ECGs were recorded during the 1st and 3rd min-
utes during anesthesia induction and 3 minutes after
administration of muscle relaxant. Intubation was
performed with a tube of appropriate size, and fur-
ther ECGs were recorded at 5 minutes and 10 min-
utes, respectively. Heart rate (HR), mean blood
pressure, peripheral oxygen saturation (SpO2), and
end-tidal carbon dioxide (ETCO2) were recorded con-
currently with all ECG records. After obtaining val-
ues at 10 minutes postintubation, surgery began.
Electrocardiographic measurements
HR was calculated from the ECG records using the
mean RR interval. The beginning of the P wave was
defined as a positive deflection from the isoelectric
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line, and the end as the point at which the positive
deflection returned to the isoelectric line [1,3–5]. 
P waves without obvious beginning and end were not
analyzed. Pwd was defined as the difference between
the longest and shortest P-wave durations. Extended
Pwd was defined as duration > 40 milliseconds
[1,3–5].
The QT interval was defined as the interval 
between the beginning of the QRS complex and 
the point at which the T wave descended onto the TP
isoelectric line [4,5,14,15]. When a U wave inter-
rupted the T wave before returning to baseline, the
QT interval was measured to the nadir of the curve
between the T and U waves. The QTc interval was
calculated using the Bazett formula; QTc (millisec-
onds) = QT measured/√RR. Extended QTc interval
was defined as a duration > 440 milliseconds [4,5,
14,15].
Subjects who had less than nine derivations on
recorded ECGs were excluded from the study [4,5].
All ECG measurements were evaluated three times by
two experts who were blinded to the group assess-
ment, and the mean values accepted. The intraob-
server and interobserver variations for Pwd were
found to be 3.1% and 3.3%, and for QT  interval, they
were 2.6% and 2.9%, respectively.
Power analysis
Using previously published data [1,16,17], interpre-
tation of an effect in either direction, and the criterion
for a significance level of 0.01, it was calculated that a
sample size of 35 per group would detect a difference
of 17 milliseconds in QTc between the intraoperative
means of the two groups with a power of 85%.
Statistical analysis
Statistical Package for the Social Sciences version 11.5
(SPSS Inc., Chicago, IL, USA) was used for data analy-
sis. One-way analysis of variance was used to compare
the averages of data with continuous measures such
as: serum sodium, potassium, calcium, chlorine and
magnesium values; Pwd; QT and QTc durations; and
HR, mean arterial pressure, ETCO2 and SpO2 values.
The paired-samples t test was used to compare intra-
group repeated measures, and the χ2 test was used to
compare data that denoted frequency, such as sex and
ASA risk category. A value of p < 0.05 was considered
to be statistically significant.
RESULTS
The groups were similar in terms of ASA risk category,
age, sex, height, weight, BMI, and serum sodium,
potassium, calcium, chlorine and magnesium levels
(Tables 1 and 2).
There was no significant difference in terms of
mean HR variation between the groups (p > 0.05).
Analysis of intragroup HR variations revealed that
HR at 5 minutes after intubation was significantly
higher than the control values (p < 0.05) (Table 3).
There was no significant difference in mean arte-
rial pressure variation between the groups (p > 0.05).
When intragroup mean arterial pressure variations
were analyzed, it was observed in both groups that
mean arterial pressure at 1 minute after induction, 
3 minutes after induction, 3 minutes after administra-
tion of muscle relaxant, and 10 minutes after intuba-
tion was significantly lower compared with control
Table 1. Demographic and anthropometric data of 
different groups*
Sevoflurane Propofol 
p
group (n = 36) group (n = 36)
Age (yr) 35.36 ± 9.85 32.86 ± 10.97 0.313
Sex, female:male 19:17 19:17 1.000
ASA (I/II) 30/6 29/7 0.759
Height (cm) 167.11 ± 7.35 168.22 ± 8.58 0.557
Weight (kg) 69.80 ± 9.41 71.47 ± 10.09 0.471
BMI (kg/m2) 24.89 ± 2.09 25.18 ± 2.37 0.578
*Data presented as mean± standard deviation or n. ASA=
American Society of Anesthesiologists; BMI=body mass index.
Table 2. Biochemical data of different groups
Normal 
Sevoflurane Propofol 
group group pvalue 
(n = 36) (n = 36)
Sodium 136–145 142.90 ± 3.92 141.80 ± 2.88 0.200
(mmol/L)
Potassium 3.5–5.5 4.44 ± 0.40 4.41 ± 0.43 0.693
(mmol/L)
Chlorine 98–110 103.97 ± 2.82 104.78 ± 2.92 0.237
(mmol/L) 
Calcium 8.4–10.2 9.49 ± 0.43 9.40 ± 0.56 0.401
(mg/dL) 
Magnesium 1.3–2.7 2.18 ± 0.15 2.15 ± 0.20 0.498
(mg/dL) 
P-wave dispersion at anesthesia induction
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values (p<0.05) (Table 3). During the study, no patients
required administration of atropine or ephedrine.
Intragroup and intergroup statistical analysis re-
vealed no significant difference in variation in SpO2
and ETCO2 (p > 0.05).
All patients included in the study had sinus
rhythm. No patients had atrioventricular or bundle-
branch block, atrial or ventricular premature beat,
tachyarrhythmia or bradyarrhythmia. When ECG
records were analyzed, no significant difference was
observed in terms of PR interval variations between
and within the groups (p > 0.05) (Table 3).
Control ECG records were similar in terms of
maximum P wave, minimum P wave, Pwd, and QT
and QTc duration (p > 0.05). In the sevoflurane group,
except for control ECGs, Pwd and QTc intervals in all
ECG records were significantly longer than those in
the propofol group (p < 0.05) (Table 3). Excluding con-
trol ECG records, maximum P-wave duration was
significantly longer in the sevoflurane group than in
the propofol group. Minimum P-wave duration was
significantly shorter in the sevoflurane group than in
the propofol group for all ECG measurements (p <
0.05) (Table 3). The sevoflurane group had longer QT
durations than the propofol group did in ECG mea-
surements at 5 minutes and 10 minutes after intuba-
tion (p < 0.05) (Table 3).
Analysis of intragroup ECG variations showed
that maximum P-wave durations were significantly
longer than the control values in the sevoflurane
Table 3. Hemodynamic and electrocardiographic data of different groups*
Control 
Induction Induction Muscle relax Intubation Intubation 
1 min 3 min 3 min 5 min 10 min
Heart rate 
(beats/min)
Sevoflurane group 76.36 ± 10.52 75.66 ± 8.46 76.27 ± 9.46 77.50 ± 11.72 86.86 ± 13.43‡ 79.30 ± 13.49
Propofol group 77.30 ± 9.76 75.88 ± 9.18 75.86 ± 9.71 76.69 ± 8.94 82.44 ± 8.66§ 77.55 ± 6.98
MAP (mmHg)
Sevoflurane group 91.62 ± 10.01 84.12 ± 11.97‡ 81.07 ± 14.04‡ 78.63 ± 13.86‡ 88.57 ± 14.16 81.09 ± 13.49‡
Propofol group 90.72 ± 12.61 82.36 ± 10.75§ 77.75 ± 10.69§ 76.83 ± 9.17§ 90.97 ± 11.37 82.86 ± 11.06§
PR interval (ms)
Sevoflurane group 155.38 ± 18.51 152.55 ± 18.29 153.19 ± 18.91 155.41 ± 18.46 154.16 ± 15.76 153.11 ± 17.52
Propofol group 153.33 ± 13.74 150.86 ± 15.48 150.75 ± 13.76 152.25 ± 18.55 154.83 ± 18.40 152.19 ± 15.29
Max. P wave 
duration (ms)
Sevoflurane group 94.16 ± 15.00 100.83±13.60†‡ 105.27±15.02†‡ 105.83±15.92†‡ 107.77 ± 13.11†‡ 105.27 ± 12.98†‡
Propofol group 93.88 ± 12.01 87.50 ± 12.73§ 86.11 ± 10.76§ 83.05 ± 9.20§ 87.77 ± 10.72§ 85.00 ± 9.10§
Min. P wave 
duration (ms)
Sevoflurane group 67.77 ± 12.21 54.16±11.30†‡ 52.22±10.98†‡ 51.38 ± 9.90†‡ 49.44±10.93†‡ 50.55 ± 9.84†‡
Propofol group 66.38 ± 13.76 60.55 ± 11.45§ 59.44 ± 11.69§ 56.66 ± 10.95§ 56.94 ± 11.42§ 56.66 ± 11.46§
P wave dispersion 
(ms)
Sevoflurane group 26.38 ± 8.99 46.66±12.42†‡ 53.05±13.48†‡ 54.44±16.46†‡ 58.33±12.76†‡ 55.00 ± 14.04†‡
Propofol group 27.50 ± 9.06 26.94 ± 9.20 26.66 ± 8.28 26.38 ± 7.61 30.83 ± 9.06 28.33 ± 9.41
QT interval (ms)
Sevoflurane group 364.02 ± 27.67 365.16 ± 29.41 365.55 ± 31.57 365.36 ± 36.44 366.50 ± 30.52† 374.63 ± 34.99†‡
Propofol group 359.72 ± 27.84 354.16 ± 19.86 357.94 ± 16.90 360.50 ± 19.31 354.72 ± 17.77 352.22 ± 22.00
QTc interval (ms)
Sevoflurane group 406.72 ± 21.53 412.00 ± 25.78† 425.50±25.64†‡ 426.80±28.59†‡ 437.88±26.12†‡ 432.50 ± 27.04†‡
Propofol group 409.38 ± 19.06 398.16 ± 19.42§ 406.05 ± 20.09 407.55 ± 21.45 411.08 ± 19.28 410.66 ± 20.86
*Data presented as mean ± standard deviation; †p < 0.05 between sevoflurane group and propofol group; ‡p < 0.05 between control
value in sevoflurane group; §p < 0.05 between control value in propofol group; QTc reflects the heart rate adjusted QT interval by
using Bazett’s formula. Induction 1 min = 1 minute after anesthesia induction; Induction 3 min = 3 minute after anesthesia induction;
Muscle relax 3 min = 3 minute after administration of muscle relaxant (vecuronium); Intubation 5 min = 5 minute after endotracheal
intubation; Intubation 10 min = 10 minute after endotracheal intubation; Max = maximum; Min = minimum; HR = heart rate;
MAP = mean arterial pressure.
group; conversely, they were significantly shorter than
the control values in the propofol group for all record
times (p < 0.05). Minimum P-wave durations in both
groups were significantly shorter compared with the
control values at all record times (p < 0.05). The sevo-
flurane group had significantly longer Pwd values
compared with the control values at all record times
(p < 0.05). In the propofol group, when Pwd duration
was compared with the control values, it was shorter
during the 1st and 3rd minutes of anesthesia induction
and at 3 minutes following veruconium administra-
tion, but the difference was not statistically significant
(p > 0.05) (Table 3).
When intragroup variations in QT durations were
analyzed for the propofol group, there was no signif-
icant difference compared with control values at any
of the record times. In the sevoflurane group, QT
duration at 10 minutes following intubation was sig-
nificantly longer compared with the control values
(p < 0.05) (Table 3).
Analysis of intragroup variations revealed that
QTc duration measured at 3 minutes after anesthesia
induction, 3 minutes following administration of mus-
cle relaxant, and at 5 minutes and 10 minutes after
intubation was significantly longer compared with the
average control QTc in the sevoflurane group (p <
0.05) (Table 3). In the propofol group, although QTc
duration measured at 1 minute and 3 minutes after
anesthesia induction and 3 minutes following admin-
istration of muscle relaxant was shorter compared
with control values, the only statistically significant
difference was found in the measurement at 1 minute
after anesthesia induction (p < 0.05) (Table 3).
DISCUSSION
Our prospective randomized study showed that Pwd
and QT and QTc durations were significantly pro-
longed in the sevoflurane anesthesia induction group
compared with the propofol group. Pwd is a simple
non-invasive electrocardiographic indicator of atrial
arrhythmias [1,3–5]. Previous studies have shown that
Pwd can be prolonged because of coronary ischemia
[18], anxiety [19], malnutrition [4] and obesity [3,20].
For this reason, our study did not include patients
with BMI < 18 and > 30, or patients with coronary
ischemia, and all patients were administered intra-
muscular midazolam as anxiolytic premedication to
prevent Pwd values from being prolonged in the con-
trol ECG records.
Propofol is known to suppress supraventricular
tachycardia [15,21–23]. It has been shown that for
patients with atrial fibrillation, propofol at doses of
1.5–2.0 mg/kg reduces atrial fibrillation during abla-
tion [24]. In another case report, a patient with atrial
fibrillation, which did not respond to 24 hours treat-
ment with amiodarone, received 50 mg propofol for
sedation prior to electrical cardioversion, and the car-
diac rhythm returned permanently to sinus [25]. The
authors of this report also stated that, in two more
cases in their clinic, atrial fibrillation similarly re-
turned to sinus rhythm after administration of 50 mg
or 75 mg of propofol [25]. Such effects of propofol are
associated with suppression of tonus, increase in vagal
tonus, changes in baroreceptor reflex sensitivity, and
its effects on atrioventricular transmission [26]. Al-
though the effects of propofol on atrial arrhythmias
have been emphasized in case reports, prospective
controlled studies on its effects on Pwd are rare. In
their study on the effects of propofol and desflurane
on Pwd, Owczuk et al [1] reported no significant
change in Pwd duration at any of the measurement
times in the desflurane group, and Pwd duration
shortened significantly during the 3rd and 5th minutes
of anesthesia in the propofol group. The same re-
searchers have emphasized that propofol causes a
significant reduction in Pwd [1]. In our study, we also
observed that, in the propofol group, Pwd duration
was shortened in comparison to the control Pwd dur-
ing the 1st and 3rd minutes of anesthesia induction and
at 3 minutes following administration of muscle relax-
ant. However, we did not encounter a statistically sig-
nificant difference in comparison to the control value.
In our literature review, we did not encounter any data
on the effects of inhalational anesthesia induction with
sevoflurane on Pwd duration. In our study, we found
that Pwd was significantly prolonged in patients who
underwent sevoflurane induction in comparison to
propofol induction. Also, we found that Pwd duration
was significantly prolonged in comparison to the con-
trol value at all record times in the sevoflurane group.
Most anesthetic agents affect the duration of QT
interval. The frequently used inhalation anesthetics
halothane and isoflurane both prolong QTc interval
[1,17]. In patients with acquired, congenital or idio-
pathic long QT syndrome, use of inhalational anes-
thetics that prolong QT interval increases the risk of
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polymorphic ventricular tachycardia and torsades de
pointes [16,27–30]. There have been cases in which
sevoflurane has been considered responsible for the
development of torsades de pointes in patients with
long QT syndrome [31,32]. In our study, we found
that there was a significant prolongation in QT and
QTc intervals when compared with control values
during inhalational induction with 7% sevoflurane.
Previous studies have focused on how sevoflurane
affects QT interval and have emphasized that sevo-
flurane prolongs the action potential period [33–36].
However, the mechanism of this effect has not been
clearly explained. It has also been emphasized that
sevoflurane, in clinically used concentrations, inhi-
bits slow potassium channels but does not have an
effect on fast potassium channels [33–36].
There is to date on consensus on the effect of pro-
pofol on QTc interval [27]. In a previous case report,
propofol shortened QT interval and QT dispersion
duration in a patient with idiopathic QT and QT dis-
persion prolongation [37]. It has been reported that
anesthesia was performed smoothly using total intra-
venous anesthesia with propofol in patients with
congenital long QT syndrome [38,39]. In a study of 60
children, propofol plasma concentrations of 3 μg/mL,
4.5 μg/mL and 6 μg/mL were reported to have no
effect on QTc. This study emphasizes that propofol
used in clinical doses does not affect myocardial repo-
larization in children, and that propofol is a good
choice in children with repolarization abnormalities
[27]. Likewise, in our study, propofol was not found
to prolong QT and QTc duration, and significantly
shortened them when compared with control values
at certain record times.
Previous comparisons of the effects of induction
with sevoflurane and propofol on QTc interval have
shown that QTc interval is significantly longer with
sevoflurane induction [29,40,41]. Paventi et al [29]
emphasized that, in the presence of agents that pro-
long QT duration, such as long QT syndrome and
hypokalemia, the relationship between sevoflurane
and QT prolongation needs to be remembered and
sevoflurane should be avoided [29]. Similarly, we
found that QTc interval duration in the sevoflurane
group was significantly prolonged in comparison
with control values and the propofol group.
Recent recommendations of the American College
of Cardiology/American Heart Association include
the use of volatile anesthetics during non-cardiac
surgery [42]. This remains controversial but it should
be remembered that the results of our study were
derived from anesthesia induction only and did not
involve the whole perioperative process. Inhalational
induction with sevoflurane for a very brief duration,
such as in our study, is too short to have a direct
effect on cardioprotection [43–45].
One limitation in our study is that the quality of
ECG recordings. We only searched Pwd, QT, and QTc
changes at induction of anesthesia, and ECG record-
ings have a certain drop-out rate because of missing
derivations and low quality. Therefore, it might be bet-
ter for the future studies to include the whole perioper-
ative process, with Holter monitoring, which would
probably, with its higher quality, document any in-
creased rate of atrial and ventricular arrhythmias.
In conclusion, propofol could be the first drug 
of choice for anesthesia induction in patients with a
predisposition to preoperative arrhythmia, and those
whose Pwd and QTc duration are prolonged in con-
trol ECG records.
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